37例晚期肿瘤患者苹果酸舒尼替尼靶向治疗的不良反应护理  

Nursing of Adverse Reaction of Sunitinib Malate Used in Target Therapy for Advanced Tumor Patients

作　　者：杨剑霞[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院综合医疗科,湖北武汉430030

出　　处：《护理学报》2013年第17期29-31,共3页Journal of Nursing（China）

摘　　要：苹果酸舒尼替尼为新型的分子靶向治疗类药物,对37例肿瘤患者采用单药口服的治疗方法,治疗中不良反应包括:手足综合征9例,皮疹5例,疲劳8例,恶心、呕吐7例,血压升高7例,白细胞减少3例,血小板减少2例,红细胞减少1例,出血3例,肝毒性3例,血栓1例。认为用药过程中,重点是给予早期的皮肤护理干预,适当的饮食调护,避免外伤和碰撞引起出血,预防感染;密切监测血压、血常规、肝功能、甲状腺功能、心功能变化,合理进行药物梯度剂量的调整,以确保药物治疗的顺利进行。In this study, a single oral dose of sunitinib malate, a new type molecule-target medicine, was given to 37 advanced tumor patients. Adverse reaction included nine ease of hand-foot syndrome, five of rash, eight of fatigue, seven of vomitting, seven of elevation of blood pressure, three of leukopenia, two of thromboeytopenia, one of erythropenia, three of bleeding, three of hepatotoxieity and one of thrombus. During the treatment, early skin nursing was a neeessarity. Balanced diet and prevention of bleeding would prevent the infection. Close monitoring of blood pressure, blood routine, function of liver, thyroid and heart then corresponding adjustment of dose contributed to the success of drug treatment.

关 键 词：苹果酸舒尼替尼 肾癌 胃肠间质瘤 肺癌 不良反应 护理 

分 类 号：R979.1[医药卫生—药品]